In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Sensus Healthcare Inc (SRTS), with a price target of $11. The company’s shares closed yesterday at $7.74.
Vendetti said:
“Sensus reported better-than-expected 4Q18 revenue and GAAP EPS. The company shipped 27 total systems in the quarter, above our estimate of 22, bringing its total installed base to 416 systems. Sculptura, the company’s intraoperative radiation therapy (IORT) system, remains on track for commercialization in 1H19. Sensus shipped its first unit in of Pennsylvania. We are rolling forward our DCF analysis by one year; as a result, we are slightly raising our PT to $11, from $10.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 5.0% and a 50.0% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Restoration Robotics Inc, Milestone Scientific, and Viveve Medical Inc.
Sensus Healthcare Inc has an analyst consensus of Moderate Buy, with a price target consensus of $9.75, a 26.0% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.88 and a one-year low of $5.00. Currently, Sensus Healthcare Inc has an average volume of 51.87K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
